Protein markers for pharmaceuticals and related toxicity
CA 2410158 A1 · Owner: Large Scale Proteomics, Corp. · Inventors: Anderson, N. Leigh; Steiner, Sandra
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Protein markers of toxicity and efficacy for drugs are determined. For example, methods and reagents are disclosed for determining whether a patient receiving an antilipemic drug, especially a statin or HMGCoA reductase inhibiting drug, is experiencing drug efficacy and/or toxicity. Individual susceptibility is also determined prior to treatment. Also drug discovery of , similar acting candidates and their likelihood of being toxic or effective is determined by analysis of all proteins in a sample simultaneously by 2dimensional gel elecrotphoresis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 1, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 1, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 1, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.